Compare HSBC Holdings plc (HSBC) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HSBC Holdings plc vs IDEXX Laboratories, Inc. — how do they compare? HSBC Holdings plc trades at $100.53 (market cap $335.21B), while IDEXX Laboratories, Inc. trades at $560 (market cap $44.48B). The key difference: HSBC Holdings plc is far larger — about 7.5× IDEXX Laboratories, Inc.'s market cap, and HSBC Holdings plc pays a 3.79% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| HSBC | IDXX | |
|---|---|---|
Market Cap | $335.21B | $44.48B |
Sector | Technology | Health |
52-Week High | $100.61 | $766.68 |
52-Week Low | $61.30 | $520.87 |
Dividend Yield | 3.79% | — |
Enterprise Value | — | $45.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $99.01, down 1.59% today but near its 52-week high of $99.47. The stock shows strong technical momentum with bullish moving averages, though oscillators suggest potential overbought conditions. Fundamentally, the bank maintains robust profitability with 30.81% net income margin and 10.89% ROE, supported by recent earnings beats and a $0.50 dividend declaration. Recent news highlights strategic moves including AI partnerships and business portfolio optimization.
HSBC presents a mixed outlook with solid fundamentals and strategic initiatives balanced against valuation concerns and regional risks. The bank's focus on AI integration and market exits could drive efficiency, but regulatory challenges and economic uncertainty pose headwinds. Analyst consensus leans cautious with 38% buy ratings, suggesting selective opportunity for long-term investors despite near-term overbought signals.
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
